Latest Survival of motor neuron Stories
-- ENDEAR Trial To Enroll 110 SMA Infants at Sites Globally CARLSBAD, Calif., Aug. 1, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
Results presented at the American Academy of Neurology meeting CARLSBAD, Calif., April 29, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
These funds were awarded as part of Families of SMA’s basic research grant program.
On track to initiate Phase 3 study in infants with SMA in the middle of this year CARLSBAD, Calif., Feb. 21, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
Average increase of 3.7 points observed in muscle function score in SMA children treated with 9 mg of ISIS-SMN Rx CARLSBAD, Calif., Feb.
--Isis will receive $9.3 million in milestone payments -- CARLSBAD, Calif., Feb. 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
SOUTH PLAINFIELD, N.J., Jan. 22, 2014 /PRNewswire/ -- PTC Therapeutics, Inc.
A recent study led by scientists from the National University of Singapore (NUS) opens a possible new route for treatment of Spinal Muscular Atrophy (SMA), a devastating disease that is the most common genetic cause of infant death and also affects young adults.
It describes the scientific strategy behind Antisense Drugs.